{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:27:22Z","timestamp":1783438042771,"version":"3.54.6"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"name":"Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development","award":["17ck0106352h0001"],"award-info":[{"award-number":["17ck0106352h0001"]}]},{"name":"National Cancer Center Research and Development Fund","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/jjco\/hyx063","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T07:51:18Z","timestamp":1492674678000},"page":"664-667","source":"Crossref","is-referenced-by-count":15,"title":["Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II\/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)"],"prefix":"10.1093","volume":"47","author":[{"given":"Kenjiro","family":"Namikawa","sequence":"first","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Tsutsumida","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Mizutani","sequence":"additional","affiliation":[{"name":"JCOG Data Center\/Operations Office, National Cancer Center, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[{"name":"JCOG Data Center\/Operations Office, National Cancer Center, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takenouchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Niigata Cancer Center Hospital, Niigata"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Uchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyushu University Hospital, Fukuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masutaka","family":"Furue","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyushu University Hospital, Fukuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saitama Medical University Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saitama Medical University Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"key\n\t\t\t\t20180315010305_hyx063C1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180315010305_hyx063C2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20180315010305_hyx063C3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315010305_hyx063C4","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180315010305_hyx063C5","first-page":"CD008955","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","volume":"6","author":"Mocellin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180315010305_hyx063C6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/annonc\/mdn001","article-title":"Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis","volume":"19","author":"Garbe","year":"2008","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180315010305_hyx063C7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","article-title":"Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update","volume":"13","author":"Ishihara","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"key\n\t\t\t\t20180315010305_hyx063C8","first-page":"41","article-title":"Clinical trials of human fibroblast interferon (Hu IFN-\u03b2) in the treatment of malignant tumors of the skin","volume":"18","author":"Ishihara","year":"1983","journal-title":"J Jpn Soc Cancer Ther"},{"key":"key\n\t\t\t\t20180315010305_hyx063C9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5227\/skincancer.1.47","article-title":"Lymphatic transportability of the locally injected interferon beta in patients with melanoma","volume":"1","author":"Yamamoto","year":"1986","journal-title":"Skin Cancer"},{"key":"key\n\t\t\t\t20180315010305_hyx063C10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jso.22029","article-title":"Local and intralesional therapy of in-transit melanoma metastases","volume":"104","author":"Testori","year":"2011","journal-title":"J Surg Oncol"},{"key":"key\n\t\t\t\t20180315010305_hyx063C11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180315010305_hyx063C12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315010305_hyx063C13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/47\/7\/664\/24356837\/hyx063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T05:03:19Z","timestamp":1521090199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/47\/7\/664\/3807295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,5,9]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyx063","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,5,9]]}}}